What if a simple test could help predict how long someone with advanced cancer might live? For patients dealing with leptomeningeal disease, a severe complication where cancer spreads to the brain and spinal cord, this question is particularly urgent. Treating this condition is tough, and current methods to assess how well treatment is working are limited. In a recent analysis of multiple studies, scientists found that testing cerebrospinal fluid for circulating tumor DNA can give valuable clues about a patient's condition. They discovered that certain DNA markers in the fluid were associated with worse survival outcomes. For example, patients with specific mutations had significantly shorter survival times. This means that by regularly monitoring these DNA levels, doctors could better tailor treatments based on how the disease is progressing. However, while these findings are promising, more research is needed to standardize how this testing is done and to understand its full potential. For patients, this could mean a future where treatments are more personalized and effective, offering hope in a challenging battle against cancer.
CSF ctDNA Status Predicts Survival in Leptomeningeal Metastases: Meta-AnalysisCan a Simple Test in Spinal Fluid Predict Survival for Cancer Patients?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Consider CSF ctDNA status to predict survival in LMD patients.
This meta-analysis aimed to assess the prognostic value of cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) in patients with leptomeningeal metastases (LMD) from solid tumors. The study included 14 studies with a total of 963 patients evaluating baseline CSF ctDNA and two studies with 26 patients assessing longitudinal ctDNA kinetics. The primary endpoint was overall survival (OS), with progression-free survival (PFS) as a secondary endpoint. The analysis found that patients with adverse baseline CSF ctDNA status, such as EGFR mutation positivity, had significantly worse OS (pooled HR 2.40, 95% CI 1.73-3.33) and PFS (pooled HR 2.45, 95% CI 1.36-4.44). Longitudinal studies indicated that increasing CSF ctDNA variant allele fraction was associated with worse OS (pooled HR 4.11, 95% CI 1.25-13.48). The heterogeneity was moderate for OS (I²=36.6%) and low for PFS (I²=15.5%) and longitudinal OS (I²=8.5%). No specific safety or adverse events were reported in relation to CSF ctDNA testing. These findings suggest that baseline and serial CSF ctDNA measurements could serve as valuable biomarkers for survival outcomes in LMD, potentially guiding therapeutic decisions and complementing clinical and radiographic assessments. The study highlights the need for prospective, standardized, multi-timepoint CSF ctDNA studies to further validate these findings and integrate CSF ctDNA monitoring into clinical practice.
What this means for you:
Testing spinal fluid for tumor DNA could change how we predict and treat advanced cancer, offering new hope. View Original Abstract ↓
PURPOSE: Leptomeningeal disease (LMD) is a devastating complication of advanced solid tumors with limited prognostic and response-assessment tools. Because LMD molecular evolution is frequently compartmentalized behind CNS barriers, cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) may provide CNS-specific molecular readouts of disease activity. We evaluated whether baseline CSF ctDNA profiles and longitudinal ctDNA kinetics associate with survival in LMD.
METHODS: We performed a systematic review and meta-analysis (PROSPERO CRD420251068543) of Embase, PubMed, Cochrane CENTRAL, WHO ICTRP, ClinicalTrials.gov, Europe PMC, and Web of Science from inception through June 2025. Eligible studies included adults with solid-tumor LMD undergoing anti-cancer therapy with CSF ctDNA assessed at baseline and/or serially and reported associations with overall survival (OS) and/or progression-free survival (PFS). Random-effects models pooled hazard ratios (HRs). Longitudinal studies were analyzed separately due to limited availability.
RESULTS: Fourteen studies (n = 963) evaluated baseline CSF ctDNA and two studies (n = 26) evaluated longitudinal kinetics. Adverse (non-reference) baseline ctDNA status (e.g., EGFR mutation positive vs. negative) was associated with inferior OS (pooled HR 2.40, 95% CI 1.73-3.33; I²=36.6%) and PFS (pooled HR 2.45, 95% CI 1.36-4.44; I²=15.5%). Longitudinally, increasing CSF ctDNA variant allele fraction was associated with worse OS (pooled HR 4.11, 95% CI 1.25-13.48; I²=8.5%). Across longitudinal reports, serial CSF ctDNA measurements tracked progression and response.
CONCLUSION: Baseline and serial CSF ctDNA measurements are associated with survival outcomes in LMD and may complement clinical and radiographic assessment. These findings support prospective, standardized, multi-timepoint CSF ctDNA studies in LMD and warrant CSF-access-enabled monitoring to inform therapeutic adaptation.
Experimental agents show response rates up to 70% in relapsed or refractory diffuse large B-cell lymphoma
New cancer therapies double response rates for tough lymphoma
Related in Oncology
DaVinci Single-Port transoral robotic surgery is feasible across multiple indications including oncology and sleep apnea
Single-Port Robot Shows Promise for Sleep Apnea Surgery
This systematic review and meta-analysis of 479 patients evaluates the feasibility of DaVinci Single-Port (SP) transoral robotic surgery (TO…
A new analysis finds single-port robotic surgery for sleep apnea is feasible, with short operating times and low blood loss.
Neoadjuvant chemoimmunotherapy achieves higher pathological complete response rates than chemotherapy alone in muscle-invasive bladder cancer
Chemoimmunotherapy Shows Higher Response Rates in Bladder Cancer
This network meta-analysis of 2234 patients with muscle-invasive bladder cancer compares neoadjuvant chemoimmunotherapy (NICT), chemotherapy…
A new analysis shows that combining chemotherapy and immunotherapy may lead to higher response rates for patients with muscle-invasive bladd…
MRI Radiomics Predicts TERTp Mutation in Glioma with Moderate Accuracy
MRI Radiomics Help Predict TERTp Mutation in Glioma Patients
Meta-analysis of 14 studies shows MRI radiomics predicts TERTp mutation in glioma with AUC 0.79; combined models improve accuracy to 0.82.
New analysis shows MRI-based radiomics can help predict specific genetic mutations in glioma, potentially aiding early diagnosis and treatme…
Comprehensive palliative care improves quality of life, survival, and symptoms in thoracic cancer patients
Palliative care improves quality of life for thoracic cancer patients
This meta-analysis of 6490 people with thoracic cancer found that comprehensive palliative care interventions improved quality of life (SMD …
Comprehensive palliative care can improve survival, manage symptoms, and boost quality of life for people living with thoracic cancers.
From Other Specialties
Individualized six-phase antithrombotic strategy leads to left ventricular thrombus resolution and neurological recovery
New strategy helps manage heart blood clots after heart attack
This case report describes an individualized six-phase antithrombotic strategy for a 27-year-old male with myocardial infarction, stroke, hy…
A tailored six-phase treatment plan helped a young man recover fully from a stroke and heart attack while successfully clearing dangerous bl…
Heterogeneous definitions and clinical inconsistencies currently hinder the accurate identification of treatment-resistant depression
New ways to define treatment resistant depression are emerging
This narrative review examines the phenotypic definition of treatment-resistant depression (TRD) and its associated biological correlates. T…
Doctors struggle to treat some types of depression because the current definition is inconsistent. New research looks at how biology and beh…
HIFU combined with ethanol ablation or GnRH-a improves intraoperative outcomes for adenomyosis treatment
HIFU Combined With Medication Shows Better Results for Adenomyosis
This network meta-analysis of 1,685 patients evaluated HIFU combined with various medications compared to HIFU alone for adenomyosis. The an…
Combining high-intensity focused ultrasound (HIFU) with specific medications may improve treatment outcomes for people with adenomyosis.
Risk-optimized use of Janus kinase inhibitors in Japanese patients with rheumatoid arthritis depends on comorbidities
New evidence helps doctors choose safer arthritis treatments for seniors
This narrative review examines the safety and risk profile of Janus kinase inhibitors (JAKi) for rheumatoid arthritis specifically within th…
Doctors are moving toward personalized plans for rheumatoid arthritis, focusing on a patient's specific health risks rather than just their …